It showed that the new generation of T2D drugs in the GLP-1 class including oral Semaglutide, subcutaneous Semaglutide and Dulaglutide, all of which were approved in recent years, attained the perfect efficiency of one. Here, GLP1R is linked to type 2 diabetes mellitus.